Biomaterial-Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future Perspectives.

O'Neill, Hugh S.; Gallagher, Laura B.; O'Sullivan, Janice; Whyte, William; Curley, Clive; Dolan, Eimear; Hameed, Aamir; O'Dwyer, Joanne; Payne, Christina; O'Reilly, Daniel; Ruiz-Hernandez, Eduardo; Roche, Ellen T.; O'Brien, Fergal J.; Cryan, Sally-Ann; Kelly, Helena; Murphy, Bruce; Duffy, Garry P.

Biomaterial-Enhanced Cell and Drug Delivery: Lessons Learned in t.pdf (1.57 MB)

Biomaterial-Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future Perspectives.

Version 2 2022-04-05, 08:28

Version 1 2019-11-22, 15:04

journal contribution

posted on 2019-11-22, 15:04 authored by Hugh S. O'Neill, Laura B. Gallagher, Janice O'Sullivan, William Whyte, Clive Curley, Eimear Dolan, Aamir Hameed, Joanne O'Dwyer, Christina Payne, Daniel O'Reilly, Eduardo Ruiz-Hernandez, Ellen T. Roche, Fergal J. O'Brien, Sally-Ann Cryan, Helena Kelly, Bruce Murphy, Garry P. Duffy

Heart failure is a significant clinical issue. It is the cause of enormous healthcare costs worldwide and results in significant morbidity and mortality. Cardiac regenerative therapy has progressed considerably from clinical and preclinical studies delivering simple suspensions of cells, macromolecule, and small molecules to more advanced delivery methods utilizing biomaterial scaffolds as depots for localized targeted delivery to the damaged and ischemic myocardium. Here, regenerative strategies for cardiac tissue engineering with a focus on advanced delivery strategies and the use of multimodal therapeutic strategies are reviewed.

Funding

This publication has emanated from research supported in part by research grants from Science Foundation Ireland (SFI) under grant number SFI/12/RC/2278 & SFI/13/IA/1840, BioAT funding bodies PRTL (Programme for Research in Third Level Institutions) Cycle 5 and European Regional Development Fund (ERDF), part of the European Union Structural Funds Programme 2007-2013, the European Research Council grant agreement n° 239685 and AMCARE grant agreement n° 604531 both from the European Union’s Seventh Framework Programme (FP7/2007-2013), and funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement n° 645911.

History

Comments

This is the peer reviewed version of the following article: O'Neill HS, Gallagher LB, O'Sullivan J, Whyte W, Curley C, Dolan E, Hameed A, O'Dwyer J, Payne C, O'Reilly D, Ruiz-Hernandez E, Roche ET, O'Brien FJ, Cryan SA, Kelly H, Murphy B, Duffy GP. Biomaterial-Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future Perspectives. Advanced Materials. 2016;28(27):5648-61, which has been published in final form at doi: 10.1002/adma.201505349. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving."

Published Citation

O'Neill HS, Gallagher LB, O'Sullivan J, Whyte W, Curley C, Dolan E, Hameed A, O'Dwyer J, Payne C, O'Reilly D, Ruiz-Hernandez E, Roche ET, O'Brien FJ, Cryan SA, Kelly H, Murphy B, Duffy GP. Biomaterial-Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future Perspectives. Advanced Materials. 2016;28(27):5648-61.